---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-24-000015"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:40:02.708189+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics Q2 revenue $187M; net loss narrows to $99M; NDAs submitted

## Summary
- Q2 total revenue $186.7M vs $213.8M YoY; DMD franchise $118M (Translarna $70M, Emflaza $47M).
- Net loss $99.2M improved from $198.9M loss; cash $1.09B after $250M Royalty Pharma put option.
- Submitted NDA for sepiapterin (PKU) and resubmitted NDA for Translarna (nmDMD) to FDA in July 2024.
- Full-year 2024 revenue guidance $700M-$750M; GAAP R&D+SG&A $740M-$835M.
- BLA for AADC deficiency gene therapy accepted with priority review; PDUFA date Nov 13, 2024.

## SEC filing metadata
- accession: 0001070081-24-000015
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008124000015/0001070081-24-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008124000015/tmb-20240808x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-24-000015
- JSON: https://secwatch.observer/filing/0001070081-24-000015.json
- Plain text: https://secwatch.observer/filing/0001070081-24-000015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.